WO2001083528A3 - Immunisation au moyen d'acide nucleique - Google Patents

Immunisation au moyen d'acide nucleique Download PDF

Info

Publication number
WO2001083528A3
WO2001083528A3 PCT/GB2001/001924 GB0101924W WO0183528A3 WO 2001083528 A3 WO2001083528 A3 WO 2001083528A3 GB 0101924 W GB0101924 W GB 0101924W WO 0183528 A3 WO0183528 A3 WO 0183528A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid sequence
influenza virus
acid immunization
antigen
Prior art date
Application number
PCT/GB2001/001924
Other languages
English (en)
Other versions
WO2001083528A2 (fr
Inventor
Joel R Haynes
Michael D Macklin
Lendon G Payne
Original Assignee
Powderject Vaccines,Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines,Inc filed Critical Powderject Vaccines,Inc
Priority to AU2001252390A priority Critical patent/AU2001252390A1/en
Priority to EP01925706A priority patent/EP1282640A2/fr
Publication of WO2001083528A2 publication Critical patent/WO2001083528A2/fr
Publication of WO2001083528A3 publication Critical patent/WO2001083528A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

L'invention concerne une réponse immunitaire à un virus de la grippe, provoquée chez un sujet par l'administration d'une composition vaccin comprenant une séquence d'acide nucléique qui code pour un antigène M2 du virus de la grippe. Cette séquence d'acide nucléique n'est pas présente dans un vecteur viral recombiné. Cette séquence d'acide nucléique est exprimée chez le sujet pour permettre que l'antigène M2 du virus de la grippe soit en quantité suffisante pour provoquer une réponse immunitaire.
PCT/GB2001/001924 2000-05-01 2001-05-01 Immunisation au moyen d'acide nucleique WO2001083528A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001252390A AU2001252390A1 (en) 2000-05-01 2001-05-01 Nucleic acid immunization
EP01925706A EP1282640A2 (fr) 2000-05-01 2001-05-01 Immunisation au moyen d'acide nucleique

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US20096800P 2000-05-01 2000-05-01
US56195100A 2000-05-01 2000-05-01
US09/561,951 2000-05-01
US60/200,968 2000-05-01
US21058000P 2000-06-08 2000-06-08
US60/210,580 2000-06-08

Publications (2)

Publication Number Publication Date
WO2001083528A2 WO2001083528A2 (fr) 2001-11-08
WO2001083528A3 true WO2001083528A3 (fr) 2002-04-25

Family

ID=27394229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/001924 WO2001083528A2 (fr) 2000-05-01 2001-05-01 Immunisation au moyen d'acide nucleique

Country Status (3)

Country Link
EP (1) EP1282640A2 (fr)
AU (1) AU2001252390A1 (fr)
WO (1) WO2001083528A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201701D0 (sv) * 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
AU2003269213B2 (en) 2002-09-27 2008-11-13 Powderject Research Limited Nucleic acid coated particles
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
WO2007126887A2 (fr) * 2006-03-27 2007-11-08 The Government Of The United States Of America Compositions immunogènes contenant des polynucléotides codant pour la protéine de matrice m2 et procédés d'utilisation
JP2010505883A (ja) 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
AU2011325857A1 (en) 2010-11-01 2013-05-02 University Of Technology, Sydney Immune-modulating agents and uses therefor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
WO1998003198A1 (fr) * 1996-07-19 1998-01-29 Merial Formule de vaccin polynucleotidique contre les pathologies du cheval
WO1999007839A2 (fr) * 1997-08-05 1999-02-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Nouvel antigene immunoprotecteur contre la grippe a et son utilisation dans la vaccination
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
WO2000002591A1 (fr) * 1998-07-09 2000-01-20 Merck & Co., Inc. Formulations de vaccins a base de polynucleotides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
WO1998003198A1 (fr) * 1996-07-19 1998-01-29 Merial Formule de vaccin polynucleotidique contre les pathologies du cheval
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
WO1999007839A2 (fr) * 1997-08-05 1999-02-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Nouvel antigene immunoprotecteur contre la grippe a et son utilisation dans la vaccination
WO2000002591A1 (fr) * 1998-07-09 2000-01-20 Merck & Co., Inc. Formulations de vaccins a base de polynucleotides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DEGANO P ET AL: "Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect? system", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 16, no. 4, 1 February 1998 (1998-02-01), pages 394 - 398, XP004099300, ISSN: 0264-410X *
LINDSTROM S ET AL: "Phylogenetic analyses of the matrix and non-structural genes of equine influenza viruses", ARCHIVES OF VIROLOGY, NEW YORK, NY, US, vol. 143, no. 8, 1998, pages 1585 - 1598, XP002174880, ISSN: 0304-8608 *
MOLDOVEANU Z ET AL: "CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 16, no. 11-12, 1 July 1998 (1998-07-01), pages 1216 - 1224, XP004124627, ISSN: 0264-410X *
OKUDA KENJI ET AL: "Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene.", VACCINE, vol. 19, no. 27, 2001, pages 3681 - 3691, XP004241786, ISSN: 0264-410X *

Also Published As

Publication number Publication date
AU2001252390A1 (en) 2001-11-12
WO2001083528A2 (fr) 2001-11-08
EP1282640A2 (fr) 2003-02-12

Similar Documents

Publication Publication Date Title
WO2006020071A3 (fr) Constructions vaccinales et combinaisons de vaccins conçues pour ameliorer l'etendue de la reaction immunitaire a diverses souches et variantes du vih
WO2000057917A3 (fr) Compositions d'adjuvant et methodes permettant d'accentuer les reponses immunitaires a des vaccins a base de polynucleotides
WO2001091536A3 (fr) Vaccin genetique qui imite l'infection virale naturelle et induit une immunite de longue duree contre les pathogenes
WO2001022992A3 (fr) Nouvelle composition
MX9702336A (es) Composiciones de vacuna.
WO2001060402A3 (fr) Vaccin antigrippal a base de proteosomes
WO2007052058A8 (fr) Vaccins influenza comprenant des combinaisons d'adjuvants particulaires et d'immunopotentiateurs
WO2003024480A3 (fr) Activation in vivo de cellules presentant un antigene en vue d'augmenter les reponses immunes induites par des particules de type virus
WO2001098333A3 (fr) Modification de l'antigene capsidique de l'hepatite b
CA2102918A1 (fr) Vaccin genetique anti-virus de l'immunodeficience
WO2004001051A3 (fr) Virus de la rougeole recombines exprimant les epitopes d'antigenes d'arn virus, et utilisation dans la preparation de compositions vaccinales
WO2000035482A3 (fr) Nouvel adjuvant pour vaccins composes de sous-unites ou de composants specifiques
WO2006020480A3 (fr) Compositions de vecteurs adenoviraux
MXPA02002483A (es) Vacuna contra vhb y vph.
WO2002087494A3 (fr) Nouveau vaccin
WO2000053767A3 (fr) Vaccins d'acide nucléique codant pour une protéine du virus respiratoire syncytial
WO2002022686A3 (fr) Proteines de fusion defensine-antigene
WO2003066094A3 (fr) Nouveau vaccin
AU1800597A (en) Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
WO2001083528A3 (fr) Immunisation au moyen d'acide nucleique
WO2004035006A3 (fr) Methodes et compositions d'immunisation contre le virus vih
HK1056830A1 (en) Mannose as intranasal vaccine adjuvant
WO2002022687A3 (fr) Proteines de fusion chimiokine virale-antigene tumoral
EP1439856A4 (fr) Vaccin antirabique recombine, preparation et utilisation de ce vaccin
WO2006091455A3 (fr) Echafaudages moleculaires destines a des immunogenes hiv-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001925706

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001925706

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001925706

Country of ref document: EP